Literature DB >> 11304906

Nutrition and prostate cancer: a proposal for dietary intervention.

E L Wynder1, D P Rose, L A Cohen.   

Abstract

In this review, we consider the evidence from geographic and metabolic epidemiology and laboratory studies with human prostate cancer cell lines and animal models that emphasizes the need for the development and implementation of a dietary intervention trial in prostate cancer patients. It is concluded that such a trial should include a reduction in total fat consumption to 15% of total calories and supplementation of the diet with selenium, vitamin E, and a soya product. The low-fat intervention would provide an appropriate reduction in the intake of any specifically targeted dietary fatty acid, such as linoleic acid or alpha-linolenic acid.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 11304906     DOI: 10.1080/01635589409514327

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  11 in total

1.  Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial.

Authors:  Maarten C Bosland; Ikuko Kato; Anne Zeleniuch-Jacquotte; Joanne Schmoll; Erika Enk Rueter; Jonathan Melamed; Max Xiangtian Kong; Virgilia Macias; Andre Kajdacsy-Balla; L H Lumey; Hui Xie; Weihua Gao; Paul Walden; Herbert Lepor; Samir S Taneja; Carla Randolph; Michael J Schlicht; Hiroko Meserve-Watanabe; Ryan J Deaton; Joanne A Davies
Journal:  JAMA       Date:  2013-07-10       Impact factor: 56.272

Review 2.  Complementary and alternative medicine in prostate cancer.

Authors:  J S Jacobson; A P Chetty
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 3.  New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer.

Authors:  Shahnjayla K Connors; Ganna Chornokur; Nagi B Kumar
Journal:  Nutr Cancer       Date:  2011-11-18       Impact factor: 2.900

4.  Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers.

Authors:  M Tanaka; K Fujimoto; Y Chihara; K Torimoto; T Yoneda; N Tanaka; A Hirayama; N Miyanaga; H Akaza; Y Hirao
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-07-14       Impact factor: 5.554

5.  Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer.

Authors:  M D Brown; C Hart; E Gazi; P Gardner; N Lockyer; N Clarke
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

6.  MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.

Authors:  Sivalokanathan Sarveswaran; Ritisha Ghosh; Shravan Morisetty; Jagadananda Ghosh
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

7.  Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin.

Authors:  Yi-Jun Wang; Yujian Huang; Nagaraju Anreddy; Guan-Nan Zhang; Yun-Kai Zhang; Meina Xie; Derrick Lin; Dong-Hua Yang; Mingjun Zhang; Zhe-Sheng Chen
Journal:  Oncotarget       Date:  2016-02-02

8.  Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats.

Authors:  M Onozawa; T Kawamori; M Baba; K Fukuda; T Toda; H Sato; M Ohtani; H Akaza; T Sugimura; K Wakabayashi
Journal:  Jpn J Cancer Res       Date:  1999-04

9.  Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells.

Authors:  T Tawadros; M D Brown; C A Hart; N W Clarke
Journal:  Br J Cancer       Date:  2012-10-04       Impact factor: 7.640

10.  Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer.

Authors:  M Brown; J-A Roulson; C A Hart; T Tawadros; N W Clarke
Journal:  Br J Cancer       Date:  2014-03-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.